Universitätsklinikum Ulm

Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple negative or luminal B/HER2 normal breast cancer (GENEVIEVE) (2016) Paepke S, Huober J, Sherko K, Eidtmann H, Untch M, Costa SD, Blohmer JU, et al. Conference contribution Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29) (2016) Von Minckwitz G, Rezai M, Tesch H, Huober J, Gerber B, Zahm DM, Hilfrich J, et al. Journal article Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer (2016) Janni WJ, Rack B, Terstappen LWMM, Pierga JY, Taran FA, Fehm T, Hall C, et al. Journal article Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study (2016) Gaß P, Fasching P, Fehm T, De Waal J, Rezai M, Baier B, Baake G, et al. Journal article Angiographic patterns of drug-eluting stent restenosis after treatment with drug-coated balloon versus balloon angioplasty: Late lumen loss subgroup analyses of the PEPCAD-DES study (2016) Rittger H, Woehrle J, Brachmann J, Hohenforst-Schmidt W, Schlundt C, Lonke S, Von Cranach M, et al. Journal article Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial (2016) Jueckstock J, Rack B, Friedl TWP, Scholz C, Steidl J, Trapp E, Tesch H, et al. Journal article CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients (2016) Rack B, Jueckstock J, Trapp E, Weissenbacher T, Alunni-Fabbroni M, Schramm A, Widschwendter P, et al. Journal article Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial (2016) Hepp P, Andergassen U, Jaezger B, Trapp E, Alunni-Fabbroni M, Friedl TWP, Hecker N, et al. Journal article Documentation Time and Effort and Associated Resources for Patients with Primary Breast Cancer from Diagnosis to End of Follow-Up - Results of a Multicentre Validation (2016) Beckmann M, Sell C, Aydogdu M, Brucker SY, Fehm T, Janni W, Kreienberg R, et al. Journal article Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8) (2016) Emons G, Kurzeder C, Schmalfeldt B, Neuser P, De Gregorio N, Pfisterer J, Park-Simon TW, et al. Journal article